Genetic determinants of drug response in heart failure

Current Cardiology Reports

Volumn 10, Issue 3, 2008, Pages 176-181

  Lowes, Brian D ^a   Buttrick, Peter M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; ALPHA 2C ADRENERGIC RECEPTOR; AMIODARONE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CYTOCHROME P450 2C9; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; POTASSIUM CHANNEL; QUINIDINE; ROSUVASTATIN; SPIRONOLACTONE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL; WARFARIN; PHARMACOLOGICAL BIOMARKER;

ADRENERGIC ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; DIGOXIN BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; HEART FAILURE; HEREDITY; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; LONG QT SYNDROME; LOW DRUG DOSE; MYOPATHY; PHARMACOGENETICS; POPULATION RESEARCH; PROCESS OPTIMIZATION; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; TOXICOGENETICS; GENETICS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; BIOMARKERS, PHARMACOLOGICAL; DIGOXIN; HEART FAILURE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TOXICOGENETICS;

EID: 45849104228     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0031-3     Document Type: Review

References (45)

1. McCarroll SA, Hadnott TN, Perry GH, et al.: International HapMap Consortium. Common deletion polymorphisms in the human genome. Nat Genet 2006, 38:86-92.
2. Przeworski M, Hudson RR, Di Rienzo A: Adjusting the focus on human variation. Trends Genet 2000, 16:296-302.
3. Feuk L, Carson AR, Scherer SW: Structural variation in the human genome. Nat Rev Genet 2006, 7:85-97.
4. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat Genet 2001, 29:306-309.
5. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
6. D'Andrea G, D'Ambrosio RL, Di Perna P, et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105:645-649.
7. Higashi MK, Veenstra DL, Kondo LM, et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
8. Jeffrey L, Anderson MD, Benjamin D, et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570.
9. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
10. Carson P, Ziesche S, Johnson G, Cohn JN: Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5:178-187.
11. Brand E, Chatelain N, Mulatero P, et al.: Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998, 32:198-204.
12. Kumar NN, Benjafield AV, Lin RC, et al.: Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. J Hypertens 2003, 21:1331-1337.
13. McNamara DM, Tam SW, Sabolinski ML, et al.: Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: Results from the A-HeFT Trial. J Am Coll Cardiol 2006, 48:1277-1282.
14. McNamara DM, Holubkov R, Postava L, et al.: Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003, 107:1598-1602.
15. Neumeister A, Charney DS, Belfer I, et al.: Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 2005, 15:143-149.
16. Small KM, Wagoner LE, Levin AM, et al.: Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002, 347:1135-1142.
17. Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667.
18. Bristow MR, Krause-Steinrauf H, Nuzzo R, et al.: Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004, 110:1437-1442.
19. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al.: A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103:11288-11293.
20. Small KM, Forbes SL, Rahman FF, et al.: A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000, 275:23059-23064.
21. Terra SG, Hamilton KK, Pauly DF, et al.: Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005, 15:227-234.
22. Kaye DM, Smirk B, Williams C, et al.: Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003, 13:379-382.
23. Shin J, Johnson JA: Pharmacogenetics of beta-blockers. Pharmacotherapy 2007, 27:874-887.
24. Lanfear DE, Jones PG, Marsh S, et al.: Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005, 294:1526-1533.
25. Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
26. Feldman DS, Carnes CA, Abraham WT, Bristow MR: Mechanisms of disease: beta-adrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005, 2:475-483.
27. Kubota T, McNamara DM, Wang JJ, et al.: Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998, 97:2499-2501.
28. McNamara DM, Holubkov R, Postava L, et al.: Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019-2026.
29. Raynolds MV, Bristow MR, Bush EW, et al.: Angiotensinconverting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993, 342:1073-1075.
30. Schut AF, Bleumink GS, Stricker BH, et al.: Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J 2004, 25:2143-2148.
31. Andersson B, Sylven C: The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996, 28:162-167.
32. Arnett DK, Davis BR, Ford CE, et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005, 11:3374-3383.
33. Rathore SS, Curtis JP, Wang Y, et al.: Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003, 289:871-878.
34. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [no authors listed]. N Engl J Med 1997, 336:525-533.
35. Comets E, Verstuyft C, Lavielle M, et al.: Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol 2007, 63:437-449.
36. Kjekshus J, Apetrei E, Barrios V, et al.: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
37. Khush KK, Waters DD, Bittner V, et al.: Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007, 115:576-583.
38. Bellosta S, PFoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl 1):III50-III57.
39. Niemi M, Schaeffeler E, Lang T, et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004, 14:429-440.
40. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, et al.: Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157-166.
41. Mohrschladt MF, van der Sman-de Beer F, Hofman MK, et al.: TaqIB polymorphism in CETP gene: The influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Human Genet 2005, 13:877-882.
42. Souza-Costa DC, Sandrim VC, Lopes LF, et al.: Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007, 193:438-444.
43. Sun Z, Milos PM, Thompson JF, et al.: Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J Mol Cell Cardiol 2004, 37:1031-1039.
44. Lehnart SE, AckerAan MJ, Benson DW, et al.: Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 2007, 116:2325-2345.
45. Wojnowski L, Kulle B, Schirmer M, et al.: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112:3754-3762.